Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of SGLT2 inhibitor in combination with ARB to preparation of medicament for treating hypertensive disease and other diseases

A technology of inhibitors and uses, applied in the field of application of SGLT2 inhibitors and ARBs in the preparation of drugs for the treatment of hypertension and other diseases, can solve problems such as failure to receive effective treatment, achieve improved therapeutic effects, and enhance the antihypertensive effect , good therapeutic effect

Inactive Publication Date: 2019-05-28
JIANGSU HENGRUI MEDICINE CO LTD
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

According to WTO estimates, about 20% of adults suffer from high blood pressure, and 75% of diagnosed patients have not been effectively treated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of SGLT2 inhibitor in combination with ARB to preparation of medicament for treating hypertensive disease and other diseases
  • Application of SGLT2 inhibitor in combination with ARB to preparation of medicament for treating hypertensive disease and other diseases
  • Application of SGLT2 inhibitor in combination with ARB to preparation of medicament for treating hypertensive disease and other diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Embodiment 1: Compound (1) and irbesartan co-administration and the pharmacodynamic effect of each individual administration on streptozotocin (STZ)-induced spontaneously hypertensive rat (SHR) diabetic nephropathy and lowering blood pressure Research.

[0030] 1. Test drug

[0031] Drug name: the complex of compound (1) and L-proline, prepared according to the method disclosed in WO2016050134; irbesartan, provided by Jiangsu Hengrui Medicine Co., Ltd.

[0032] Preparation method: the complex of compound (1) and L-proline is prepared with 0.5% CMC-Na / 1% Tween 80 (w / v) deionized water; irbesartan is prepared with 0.5% CMC-Na / 1 % Tween 80 (w / v) deionized water preparation.

[0033] 2. Experimental animals

[0034] Wistar Kyoto rats: male, purchased at 8-9 weeks old, with a purchased weight of 175-205g;

[0035] SHR: male, purchased at 8-9 weeks old, with a purchased body weight of 175-205 g.

[0036] All were purchased from Beijing Weitong Lihua Experimental Animal T...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of an SGLT2 inhibitor in combination with an ARB to preparation of a medicament for treating hypertensive disease and other diseases. Specifically, the SGLT2 inhibitor is selected from a compound (1) or a complex thereof or a medicinal salt thereof or a stereisomer thereof; the angiotensin II receptor antagonist (ARB) is selected from losartan, valsartan, irbesartan, candesartan, tasosartan, azilsartan, eprosartan, olmesartan or telmisartan. The general formula of the compound (1) is shown in the description.

Description

technical field [0001] The invention relates to the use of SGLT2 inhibitor combined with angiotensin II receptor antagonist in the preparation of medicines for preventing or treating diseases such as hypertension. Background technique [0002] Hypertension is a common disease. According to WTO estimates, about 20% of adults suffer from high blood pressure, and 75% of diagnosed patients fail to receive effective treatment. Deaths due to hypertension account for about 50% of the incidence of cardiovascular disease, increasing year by year, disability rate is also on the rise, and the mortality rate remains high. According to domestic clinical statistics, a drop in blood pressure of 1.20 / 0.67Kpa can prevent about 450,000 people from dying of stroke every year. Studies have shown that when blood pressure is lowered by 0.67Kpa, cardiovascular risk is reduced by 30%. With the increase of blood pressure, the risk of stroke and coronary artery events increases. Hypertension is th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K31/357A61K31/4184A61P9/12A61P13/12A61P3/10
Inventor 陈婵曹国庆杨昌永张连山
Owner JIANGSU HENGRUI MEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com